230 related articles for article (PubMed ID: 24850228)
21. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.
Katagiri H; Fujikoshi S; Suzuki T; Fujita K; Sugiyama N; Takahashi M; Gomez JC
BMC Psychiatry; 2013 Jan; 13():20. PubMed ID: 23311957
[TBL] [Abstract][Full Text] [Related]
22. A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation.
Anand E; Berggren L; Deix C; Tóth Á; McDonnell DP
Neuropsychiatr Dis Treat; 2015; 11():1349-57. PubMed ID: 26064053
[TBL] [Abstract][Full Text] [Related]
23. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.
Mauri MC; Maffini M; Di Pace C; Reggiori A; Paletta S; Moliterno D; Rovera C; Altamura CA
Int J Psychiatry Clin Pract; 2015 Jun; 19(2):99-105. PubMed ID: 25547438
[TBL] [Abstract][Full Text] [Related]
24. Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.
Chartier F; Rouillon F; Berggren L; Jamonneau I; Falissard B; Llorca PM
Encephale; 2017 Aug; 43(4):303-310. PubMed ID: 28709669
[TBL] [Abstract][Full Text] [Related]
25. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
[TBL] [Abstract][Full Text] [Related]
26. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
27. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
28. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
[TBL] [Abstract][Full Text] [Related]
29. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.
Kryzhanovskaya LA; Xu W; Millen BA; Acharya N; Jen KY; Osuntokun O
J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):157-65. PubMed ID: 22372514
[TBL] [Abstract][Full Text] [Related]
30. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
Guina J; Roy S; Gupta A; Langleben DD; Elman I
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
[TBL] [Abstract][Full Text] [Related]
31. Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.
Ascher-Svanum H; Novick D; Haro JM; Bertsch J; McDonnell D; Detke H
BMC Psychiatry; 2013 Sep; 13():224. PubMed ID: 24041270
[TBL] [Abstract][Full Text] [Related]
32. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
[TBL] [Abstract][Full Text] [Related]
33. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.
Kwon JS; Choi JS; Bahk WM; Yoon Kim C; Hyung Kim C; Chul Shin Y; Park BJ; Geun Oh C
J Clin Psychiatry; 2006 Apr; 67(4):547-53. PubMed ID: 16669719
[TBL] [Abstract][Full Text] [Related]
34. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.
Witte MM; Case MG; Schuh KJ; Ascher-Svanum H
Curr Med Res Opin; 2012 Mar; 28(3):315-23. PubMed ID: 22236137
[TBL] [Abstract][Full Text] [Related]
35. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.
Hardy TA; Henry RR; Forrester TD; Kryzhanovskaya LA; Campbell GM; Marks DM; Mudaliar S
Diabetes Obes Metab; 2011 Aug; 13(8):726-35. PubMed ID: 21435142
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine: a review of rapid and long-acting parenteral formulations.
Owen RT
Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
Frampton JE
Drugs; 2010 Dec; 70(17):2289-313. PubMed ID: 21080745
[TBL] [Abstract][Full Text] [Related]
39. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
40. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
Gastpar M; Masiak M; Latif MA; Frazzingaro S; Medori R; Lombertie ER
J Psychopharmacol; 2005 Sep; 19(5 Suppl):32-8. PubMed ID: 16144784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
